- Home
- NKTR vs PCN Comparison
NKTR vs PCN Comparison
Compare NKTR & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKTR | PCN |
|---|---|---|
| Founded | 1990 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.8M | 916.0M |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | NKTR | PCN |
|---|---|---|
| Price | $36.10 | $12.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $111.83 | N/A |
| AVG Volume (30 Days) | ★ 688.3K | 218.7K |
| Earning Date | 03-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.48 | $10.70 |
| 52 Week High | $66.92 | $14.48 |
Technical Indicators
Market Signals| Indicator | NKTR | PCN |
|---|---|---|
| Relative Strength Index (RSI) | 34.41 | 55.15 |
| Support Level | $35.03 | $12.72 |
| Resistance Level | $38.29 | $12.87 |
| Average True Range (ATR) | 2.30 | 0.06 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 18.73 | 69.05 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.